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Plasma levels of immunoreactive atrial 
natriuretic factor increase during 
supraventricular tachycardia 
A significant diuretic and natriuretic response occurs during paroxysmal supraventricular 
tachycardia @VT). Although the diuresis may be secondary to suppression of vasopressin 
secretion, the etiology of the natriuresis remains unexplained. To determine if atrial natriuretic 
factor (ANF) could contribute to the polyuric response during SVT, 10 patients were studied: five 
during spontaneous SVT and five during simulated SVT produced by rapid simultaneous atrial and 
ventricular pacing. Plasma immunoreactive ANF (IR-ANF) levels measured by radioimmunoassay 
were obtained at baseline (before and/or 24 to 48 hours after SVT) and after at least 15 minutes 
of SVT in all patients. During spontaneous and simulated SVT, IR-ANF was significantly elevated 
(mean k SE; 275 + 88 pmol/L) compared to baseline (28 i 7 pmol/L; p = 0.0036). Similar 
increases in If?-ANF were noted during both simulated and spontaneous SVT. To determine if this 
IR-ANF release was related to the increase in heart rate or the rise in right atrial pressure during 
SVT, IR-ANF levels were also measured in five patients with sinus tachycardia and in six patients 
with congestive heart failure. IR-ANF was significantly related to right atrial pressure (r = 0.93; 
p = 0.0009) but not to heart rate (r = 0.46). Thus, IR-ANF is elevated during SVT and may 
contribute to the natriuretic response. The stimulus to IR-ANF secretion during SVT appears to be 
related to the rise in right atrial pressure rather than to the increase in heart rate. (AM HEART J 
1986; 112:923.) 
John M. Nicklas, M.D., Lorenzo A. DiCarlo, M.D., Patrick T. Koller, M.D., 
Fred Morady, M.D., Emily A. Diltz, M.D., Yoram Shenker, M.D., 
and Roger J. Grekin, M.D. Ann Arbor, Mich. 
A diuresis has been reported to occur in 20 % to 50% 
of episodes of paroxysmal supraventricular tachy- 
cardia (SVT).l*P Typically, this response occurs with 
heart rates greater than 120 bpm after a duration of 
at least 10 to 30 minutes.1+2 A polyuric response has 
also been noted during episodes of atrial fibrillation, 
atrial flutter, and ventricular tachycardia. The char- 
acteristics of the diuresis during SVT include an 
increase in urine flow, volume, free water clearance, 
and sodium excretion and a decrease in urine osmo- 
1ality.l.” 
One possible pathophysiologic mechanism for this 
polyuric response during SVT is an increased secre- 
tion of a natriuretic factor or hormone. Recently, 
vasoactive peptides, termed atrial natriuretic factors 
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(ANF), have been isolated from animal”” and 
human7 atria1 tissues, sequenced, and synthesized.6-k 
Infusion of synthetic human ANF into animals has 
been demonstrated to produce an increase in urine 
sodium, potassium, and chloride excretion, an 
increase in glomerular filtration rate and urine flow, 
an inhibition of aldosterone secretion, a relaxation 
of smooth muscle, and a systemic hypotensive 
effect?-” Infusion of synthetic human ANF into 
normal human volunteers produced a significant 
natriuresis, kaliuresis, and diuresis.‘“, lR In recent 
communications, plasma levels of ANF were report- 
ed to increase during paroxysmal SVT.13-‘” In the 
present study, we have utilized a recently developed 
radioimmunoassay for ANF to determine the levels 
of immunoreactive ANF (IR-ANF) in human sub- 
jects during episodes of spontaneous and simulated 
SVT. 
METHODS 
Ten patients were studied; five were observed during 
spontaneous episodes of SVT and five underwent rapid 
simultaneous pacing of the atrium and ventricle to simu- 
late WT. The five patients with spontaneous SVT were 
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BEFORE SVT DURING SVT AFTER SVT 
Fig. 1. Plasma IR-ANF levels drawn before, during, and 
24 to 48 hours after SVT. Open circles = spontaneous 
SVT; filled circles = simulated SVT. 
17, 52, 53, 57, and 71 years old, respectively; four were 
women and one was a man. A history of recurrent episodes 
of SVT was obtained from all five patients. One patient 
underwent electrophysiologic study (EPS) and was found 
to have an accessory atrioventricular pathway. The mech- 
anism of the paroxysmal SVT was unknown in the other 
four patients. 
The five patients undergoing paced simulation of SVT 
were 27, 35, 45, 52, and 54 years old, respectively; three 
were men and two were women. All five patients received 
simultaneous atrioventricular pacing during EPS. Indica- 
tions for EPS included a history of Wolff-Parkinson- 
White syndrome in two patients, paroxysmal ventricular 
tachycardia and near syncope in one, symptomatic brady- 
cardia in one, and recurrent palpitations in one. Accessory 
bypass pathways were demonstrated in the two patients 
with Wolff-Parkinson-White syndrome, sustained ven- 
tricular tachycardia was induced in the patient with near 
syncope, and results of EPS were normal in two patients. 
There was no history of angina or congestive heart failure 
in any of these 10 patients. 
The five patients with spontaneous episodes of SVT 
had heart rates of 148,160,177,186, and 216 bpm. Plasma 
samples for ANF were collected after an arrhythmia 
duration of at least 20 minutes. In 4 of these patients, 
samples were drawn both during and 24 to 48 hours after 
the episode of SVT. In one patient SVT occurred sponta- 
neously before scheduled EPS with a baseline level having 
been drawn before the arrhythmia began. All samples 
were drawn from peripheral venous sites. 
The five patients who underwent rapid atrioventricular 
pacing were studied in the electrophysiologic laboratory 
preceding scheduled EPS. A 6F bipolar, central-lumen 
electrode catheter, with an interpolar distance of 1 cm, 
was inserted into the right femoral vein by means of the 
Seldinger technique. A second 6F bipolar catheter was 
positioned in the right ventricular apex by means of the 
same technique. Forty milliliters of blood was drawn from 
the femoral vein cannula immediately before catheter 
placement. In one patient, SVT occurred spontaneously 
during catheter positioning. The patient was observed for 
15 minutes and repeat blood samples were obtained; SVT 
was terminated by rapid atria1 pacing. If SVT did not 
occur spontaneously during catheter placement, then 
atrioventricular pacing was performed for 15 minutes with 
an atrioventricular interval of 0 msec, using a standard 
external dual-chamber pulse generator (Medtronic model 
5330) and a current twice diastolic threshold. After 15 
minutes of pacing at a rate of 160 bpm, a blood sample was 
drawn and pacing was then terminated. Surface ECGs 
were continuously recorded at 25 to 50 mm/set paper 
speed with the use of standard Electronics for Medicine 
recording equipment (VR 12, Honeywell Corporation, 
Pleasantville, N.Y.). Twenty-four hours after the pacing 
study, plasma samples were collected again for determina- 
tion of IR-ANF. 
Plasma samples for IR-ANF were obtained serially from 
one of the patients during and following a spontaneous 
episode of paroxysmal SVT. This patient was a 52. 
year-old man with a history of recurrent paroxysmal SVT. 
The patient was observed for 20 minutes at a heart rate of 
186 bpm and remained hemodynamically stable. Blood 
samples were drawn after 20 minutes of arrhythmia, and 
SVT was then terminated by carotid massage. Blood 
samples were also collected at 5, 10, 20, 30, 40, and 60 
minutes following termination of SVT. A follow-up blood 
specimen was drawn 24 hours later. 
Five patients with no known heart disease were studied 
during sinus tachycardia to determine the effect of heart 
rate alone on IR-ANF levels. These patients included two 
men and three women who were 22,42,44,53, and 71 years 
old. Heart rates during sinus tachycardia were 102, 105, 
112, 142, and 161 bpm. Plasma samples for ANF were 
collected during tachycardia lasting at least 20 minutes. 
Six patients with congestive heart failure were studied 
to determine the effect of elevated right atria1 pressure on 
IR-ANF levels. They included three men and three 
women who were 40,60,61,62,69, and 80 years old. Three 
patients had ischemic cardiomyopathies; two were idio- 
pathic and one was thought to be alcoholic in origin. Heart 
rates during plasma collection were 68, 76,80,86,103, and 
109 bpm. Right atria1 pressure was measured in five 
patients with congestive heart failure and three patients 
before and during simulated SVT. 
All blood specimens were collected in tubes containing 
EDTA, placed on ice, and centrifuged at 4’ C with the use 
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of a refrigerated centrifuge. The plasma samples were 
stored at -70’ C and extracted by means of Cl8 octade- 
cylsilane cartridges (Sep-Pak, Waters, Milford, Mass.). 
The radioimmunoassay was performed with the use of an 
antibody against I-28 a-human atria1 natriuretic polypep- 
tide (c+hANP) purchased from Peninsula Laboratories. 
Synthetic atriopeptin III was iodinated with chloramine T 
and separated by high-pressure liquid chromatography. 
Monoiodinated peptide was used as a tracer. The com- 
plete procedure has been previously described and test- 
ed.16 
Group differences between patients at baseline and 
during SVT were compared by means of a paired t test. All 
group values are expressed as mean * standard error of 
the mean. Linear regression analysis was used to examine 
relationships between plasma IR-ANF levels and other 
variables. All measurements obtained during normal sinus 
rhythm before SVT and 24 or more hours after SVT were 
assumed to be basal levels. In those instances in which 
levels were obtained both before and after SVT, the mean 
of these values was used. 
RESULTS 
The plasma concentrations of IR-ANF obtained 
in all patients with SVT are presented in Fig. 1. 
Three patients had samples drawn before, during, 
and 1 day following SVT. Three patients had sam- 
ples drawn only before and during SVT. Four 
patients with spontaneous SVT had samples drawn 
during SVT and 24 hours later. The mean basal level 
of IR-ANF during normal sinus rhythm (NSR) was 
28 k 7 pmol/L. This was not significantly different 
from the level in normal volunteers of 18 + 2 pmol/ 
L, as determined by our laboratory (p = NS).16 In 
every case there was an increase in plasma IR-ANF 
concentration during SVT compared to baseline 
levels during NSR. The mean plasma IR-ANF level 
during SVT was elevated, 275 f 68 pmol/L 
(p = O.OOSS), compared to basal levels. Similar ele- 
vations of plasma IR-ANF occurred in patients with 
spontaneous and simulated SVT. Plasma IR-ANF 
levels obtained before SVT (20 k 8 pmol/L) were 
similar to those obtained 24 to 48 hours after SVT 
(32 r 7 pmoI/‘L). 
Serial plasma IR-ANF samples obtained from one 
patient during and following a spontaneous episode 
of SVT are shown in Fig. 2. This patient demon- 
strated a dramatic elevation in plasma IR-ANF 
concentration during SVT (659 pmol/L) compared 
to levels at baseline NSR obtained 24 hours later (33 
pmol/L). The samples obtained reveal a rapid 
decrease in IR-ANF during the first 10 minutes 
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Fig. 2. Plasma IR-ANF concentrations drlring and after 
a single episode of spontaneous SVT. lnitial sample 
drawn, after 20 minutes of SVT (heart rate 186 bpm), is 
indicated at time 0 minutes. SVT was terminated imme- 
diately after the initial specimen was obt,ained. 
Levels of plasma IR-ANF in patients during SVT 
(275 -t 68 pmol/L) are compared with those from 
patients with sinus tachycardia (38 L 8 pmol/L) and 
congestive heart failure (316 -t 91 pmol/L) in Fig. 3. 
There was no relationship between IR-ANF levels 
and sex (males = 158 k 75 pmol/L, females = 103 _+ 
57 pmol/L; p = NS), age (r = 0.29; p = NS), or heart 
rate (r = 0.46; p = NS). 
Right atria1 pressure was significantly related to 
IR-ANF levels (r = 0.93; p = 0.0009j at baseline in 
the patients with SVT and congestive heart failure 
as shown in Fig. 4. During SVT, right atria1 pressure 
and plasma IR-ANF rose in three patients from 
1.9 + 1.3 to 6.7 -+ 0.8 mm Hg and from 13 2 9 to 
179 +- 130 pmol/L, respectively. The predicted IR- 
ANF level during SVT for these patients was 151 
pmol/L. 
DISCUSSION 
The pathophysiology underlying the diuretic 
response associated with SVT has been only partial- 
ly elucidated. Animal studies have shown that the 
reflex diuretic response which occurs during rapid 
atria1 pacing can be inhibited by prior hypophysec- 
tomy, suggesting a neurohumoral control mecha- 
nism.” A recent report demonstrated that in a 
patient experiencing an episode of atrioventricular 
nodal tachycardia, plasma and urine vasopressin 
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NSR ST SVT CHF 
Fig. 3. Plasma IR-ANF levels in patients with normal 
sinus rhythm (NSR), sinus tachycardia (ST), supraventri- 
cular tachycardia @VT), and congestive heart failure 
(CHF) . 
levels were suppressed. l8 Thus the increased free 
water clearance during SVT could be linked to a 
suppression of vasopressin. Left atria1 stretch recep- 
tors and vagal afferent pathways have been impli- 
cated in the mediation of vasopressin inhibition. 
Distention of the left atrium by inflation of a balloon 
within that chamber produces a reflex water diuresis 
which can be prevented by prior cervical vagotomy 
and cardiac denervation.1g*20 During left atria1 dis- 
tention a decrease in plasma vasopressin concentra- 
tion has been demonstrated to occur.21 Thus condi- 
tions associated with an increase in left atria1 pres- 
sure may stimulate atria1 stretch receptors and 
afferent parasympathetic pathways producing a 
suppression of vasopressin release. Since SVT is 
associated with an increase in both the mean atria1 
pressure and the amplitude of atrial pressure pulsa- 
tions,22 this may be the mechanism through which 
the reflex water diuresis is stimulated. Although 
vasopressin inhibition may account for the increase 
in free water clearance during SVT, it does not 
explain the associated natriuresis. 
This study demonstrates thta IR-ANF is signifi- 
cantly increased during episodes of SVT. The levels 
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Fig. 4. Linear regression of plasma levels of IR-ANF as a 
function of right atria1 (RA) pressure. 
found to be almost tenfold higher than those during 
normal sinus rhythm and returned to baseline with- 
in 24 hours. Similar increases in plasma IR-ANF 
occurred in patients with spontaneous SVT and in 
patients with simulated SVT, suggesting that the 
phenomenon was not simply secondary to electrical 
stimulation of the atrium during pacing. The data 
collected from a single patient during spontaneous 
SVT suggest that the IR-ANF elevation is a tran- 
sient response that occurs during the arrhythmia 
and rapidly decreases following termination of the 
event. The presence of elevated IR-ANF levels 1 
hour after termination of SVT suggests either con- 
tinued release of IR-ANF or a plasma half-life 
greater than 10 minutes. Since preliminary results 
imply that the half-life of the polypeptide in 
humans is less than 5 minutes, the first possibility 
appears most likely. 13zz3 Inactive forms of ANF, 
which are immunoreactive but with longer half- 
lives, could also account for this difference. 
The relationship of these elevations in plasma 
IR-ANF to a natriuresis is supported by previous 
infusion studies in humans. Absolute IR-ANF levels 
between 40 and 110 pmol/L, produced by infusion of 
a-hANP in healthy subjects, have been associated 
with increases in urinary sodium concentration.‘3 
Bolus infusions of smaller total doses of a-hANP 
yielded significant increases in urinary volume (2~) 
and sodium (4x) compared to placebo.12 Thus the 
plasma IR-ANF levels during SVT in this study 
appear to have been sufficiently high to produce a 
natriuresis in at least six of the patients. 
The large variability in the individual absolute 
and relative increases in IR-ANF during SVT may 
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be clinically significant. Although IR-ANF signifi- 
cantly increased from basal levels during the 
arrhythmia in all patients, a diuretic response asso- 
ciated with SVT occurs in only 20% to 50% of 
episodes.‘*2 The absence of diuresis despite a rise in 
IR-ANF may be the result of several factors. Again, 
the assay utilized may measure not only active ANF 
peptides but also inactive precursor forms. More 
likely, threshold concentrations sufficient to produce 
a diuretic response may not be achieved in every 
case. In addition, the stimulus for natriuresis during 
SVT may be multifactorial, depending not only 
upon changes in plasma ANF concentrations but 
also upon other neural, humoral, and hemodynamic 
factors. 
This study suggests that the primary stimulus for 
release of ANF during SVT is a rise in right atria1 
pressure and not the increase in heart rate, per se. 
Patients with sinus tachycardia had no significant 
increase in IR-ANF, and there was no relationship 
between the peak IR-ANF level and the SVT heart 
rate. Increasing atria1 pressure in rats through intra- 
venous infusion of saline solution24 or intraatrial 
balloon dilatationz5 has also been reported to 
increase plasma ANF. The rise in right atria1 pres- 
sure during SVT in this study was, in part, the result 
of simultaneous contraction of the atrium and ven- 
tricle with the tricuspid valve closed. Right atrial 
pressure may fall with sinus tachycardia when this 
valve remains open during atrial systole. Thus the 
relatively small rises in IR-ANF previously reported 
during atrial pacing may be secondary to smaller 
increments in right atria1 pressure.13-‘5 The present 
study, however, does not uniquely define right atria1 
pressure as the primary determinant of ANF release. 
Other hemodynamic variables may be even more 
closely related. Atrial distention rather than intra- 
atria1 pressure may be the final stimulus. 
The IR-ANF assay used in this study has high 
affinity for hANP (95% to 100% binding) and 
essentially no cross reactivity with furosemide, 
angiotensin I, angiotensin II, bradykinin, cosyntro- 
pin, a-MSH [a-melanocyte stimulating hormone], 
somatostatin, P-endorphin, or vasopressin 
(<0.2% ).16 Although, as with any radioimmunoas- 
say, inactive forms ‘of the polypeptide may have 
been measured, the specificity of the assay for 
biologically active ANF appears to be high. 
Reversed-phase, high-performance liquid chroma- 
tography of human plasma extracts before and after 
exogeneous hANP administration has shown only 
one major peak with a retention time similar to that 
of hANP.26 This suggests that inactive forms of the 
polypeptide do not circulate and that the IR-ANF 
assay used in this study primarily detected biologi- 
cally active ANF. 
The observations from this study suggest that the 
mechanism behind the natriuretic and diuretic 
responses to SVT may involve the release of ANF. 
The release of ANF, like the inhibition of vasopres- 
sin, appears to be mediated by hemodynamic 
changes in the atrium. Paroxysms of SVT may 
stimulate the release of IR-ANF by increasing 
intraatrial pressure. The combination of decreased 
vasopressin and increased ANF during SVT may 
thus explain both the increase in free water clear- 
ance and the increase in urinary sodium excretion 
associated with this arrhythmia. These proposed 
physiologic reflexes emphasize the importance of 
the atrium in the regulation of fluid and electrolyte 
homeostasis. 
This study imputes a possible role for ANF in the 
natriuresis associated with SVT. Additional obser- 
vations must be made to verify its role. The natri- 
uresis must be documented by careful sampling of 
urinary flow and electrolytes, and the renal response 
to ANF infused to levels obtained during SVT must 
be determined. Finally, the mechanism through 
which ANF is released must be further defined. 
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Ventricular arrhythmias during reperfusion 
Accelerated idioventricuiar rhythm has been used as a marker for coronary reperfusion. The 
incidence of accelerated idioventricuiar rhythm and ventricular tachycardia was evaluated in 52 
consecutive patients undergoing thromboiysis with intracoronary streptokinase during acute 
myocardiai infarction. Complete lbhour Hoiter recordings during and after intracoronary 
streptokinase were obtained in 39 patients. Reperfusion was documented in 17 patients (44%), 
no reperfusion in 14 (36%), and subtotal occlusion in eight (20%). Accelerated idioventricuiar 
rhythm occurred in 83%, 57%, and 83% of patients by group, respectively (p > 0.05). Ventricular 
tachycardia occurred in lOO%, 71%, and 100% of patients by group, respectively (p < 0.05). 
These data demonstrate that accelerated idioventricuiar rhythm is not specific for reperfusion 
and cannot be used as a marker for this event, and that ventricular tachycardia is more common 
with reperfusion and subtotal occlusion. (AM HEART J 1986;112:928.) 
Frederick C. Miller, M.D., Mitchell W. Krucoff, M.D., Lowell F. Satler, M.D., 
Curtis E. Green, M.D., Ross D. Fletcher, M.D., Albert A. Del Negro, M.D., 
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Nonsurgical reperfusion for acute myocardial infarc- 
tion has become a widely accepted intervention. 
Noninvasive markers for successful reperfusion, 
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such as specific arrhythmias, resolution of ST seg- 
ment shift, and creatinine-kinase enzyme curves, are 
undergoing evaluation for use in the determination 
of candidates who might benefit from angiography 
after receiving an intravenous thrombolytic agent. 
Accelerated idioventricular rhythm has been noted 
at the moment of reperfusion with intracoronary 
streptokinase’ and has shown promise as such a 
marker. A systematic quantification of ventricular 
tachyarrhythmias during thrombolytic therapy with 
